Half-year report 2017

Berlin, 31.08.2017 – M1 Kliniken AG will publish its interim report in the course of the day. A strong first half-year is the basis for the continuation of the company’s growth:

• Sales growth of 20 % compared to previous year’s figures to EUR 22.3 million
• Operating profit increases by 36 % compared to previous year’s figures to EUR 4.2 million
• EBIT margin rises to just under 19 %

M1 Kliniken AG, the operator of the largest inpatient clinic for aesthetic breast surgery in Germany, has developed very satisfactorily as a result of increasing demand for plastic and aesthetic beauty treatments due to its price and quality leadership.

Revenues in the reporting period rose by 20 % to EUR 22.3 million. On this basis, an EBIT of EUR 4.2 million was achieved, which exceeded the previous year’s result by 36 % and almost matched the EBIT of the full previous year (EUR 4.4 million). The EBIT margin rose to just under 19 %.

With currently more than 100,000 treatments per year, M1 Kliniken AG remains on a successful
growth path. Another medical center was opened in Leipzig in March 2017, and further openings will follow in the second half of 2017. The development of our own M1-beauty product line started in the first half-year. Marketing is expected to begin in the coming financial year. The transfer of the business model to similar segments in the health care sector for self-payers is currently being examined.

On June 30, 2017, a dividend of Eur 0.30 / share was paid to the shareholders. The operational
development of the company in the second half of the year will be characterized by the
establishment of further medical centers.

In August 2017, Bankhaus Metzler began the coverage of M1 Kliniken AG for the first time. In its initial assessment, the bank recommends the “Buy” recommendation. The price target is EUR 16.00.